Roger Gomis

Institut de Recerca Biomèdica de Barcelona

Life & Medical Sciences

Dr. Roger Gomis is an ICREA Research Professor and a member of the Oncology Program at the Institute for Research in Biomedicine, Barcelona. He received his PhD in biochemistry from the University of Barcelona in 2002, and was a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center in Prof. Joan Massagué's laboratory. In 2007, he assumed his current position. Dr. Roger Gomis is interested in how growth factors, signaling pathways, and gene expression programs control normal cell behavior and cancer cell metastasis. Driven by his interest in the problem of metastasis, which is the cause of 90% of cancer deaths, his laboratory is pursuing the molecular and genetic mechanisms of metastasis. In particular, the team focuses on identifying and functionally validating genes that enable cancer to metastasize clinically relevant sites. In 2012 Roger founded Inbiomotion as an ICREA and IRB Barcelona spin-off company from his laboratory research.

Research interests

Intricate signalling networks control cell division, differentiation, movement, organization and death. Cancer cells disobey these signals during tumour progression and metastasis, which is the final step in 90% of all fatal solid tumours. Metastasis is therefore a grave public health problem and consequently a field of considerable pharmaceutical interest. A major research focus of our group is to identify and understand the genes and functions that allow tumor cells to achieve metastatic colonization of vital organs. As we understand more about the biology of BC cells, we can begin to address how best to treat this form of disease. Key to determining whether dormant solitary cells or micrometastases represent valid targets is knowledge of the underlying biology of dormancy and the probability of cells progressing to active metastatic growth. This progression is poorly understood in preclinical models and even less so clinically and has become of our interest.

Selected publications

- Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay, ... Carracedo A, Gonzalez-Suarez E, Nanjundan M, Cortes J, Lazaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, GomisRR & Pujana MA 2017, 'Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition', Oncogene, 36, 19, 2737 - 2749.

- Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet JJ, Tercero JC, Rojo F, Greogory W & Gomis RR 2017, 'Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the internation, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial', Lancet Oncology, 18:1543-1552. 

- Gomis RR* & Gawrzak S 2017, 'Tumor cell dormancy', Molecular Oncology, 11, 1, 62 - 78.  

- Massagué J, Batlle E & Gomis RR 2017, 'Understanding the molecular mechanisms driving metastasis', Mol. Oncol., 11, 1, 3–4.

- Cejalvo JM, Martínez de Dueñas E, Galván P, García S, Burgués O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero A, Muñoz M, Nucíforo P, Vidal M, Pérez RM, Chacón JL, Caballero R, Gascón P, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell, J, Gomis RR, Lluch A & Prat A 2017, 'Intrinsic subtype and gene expression changes between primary and metastatic breast cancer', Cancer Research, 77, 9, 2213 - 2221.

- Seoane J* & Gomis RR* 2017, 'TGFβ family signaling in tumor suppression and cancer progression', Cold Spring Harbor Perspectives in Biology, 9:a022277.

Selected research activities

  • Co-Organizer 2018 Mechanisms of Metastasis Meeting. BBVA Biomed Conferences. Barcelona
  • 2017-2018 Member of Review Committee of Breast Cancer Now’s Research Unit. Breast Cancer Now (UK)
  • 2017 Member of the Vallformosa Foundation Research Award Committee
  • Scientific Advisory Board Member of GEICAM (Grupo Español de Cáncer de Mama) (Spain) (2016-open)